



August 5, 2021

Toyobo Co., Ltd  
 Stock Code: 3101 (TSE1)  
 Representative: Ikuo Takeuchi, President & Representative Director  
 Contact Person: Sonoko Ishimaru, General Manager,  
 Corporate Communication Department  
 TEL: +81-6-6348-3044

## Notice of Revision of Consolidated Earnings Forecasts

In light of recent developments, the Company announces that it has revised its consolidated forecasts announced on May 10, 2021 at the meeting of the Board of Directors held on August 5, 2021.

### 1. Revision to the forecasts for fiscal year ending March 31, 2022 (From April 1, 2021 to March 31, 2022)

|  | Net sales       | Operating profit | Ordinary profit | Profit attributable to owners of parent | Net profit per share |
|--|-----------------|------------------|-----------------|---|----------------------|
|  | Millions of yen | Millions of yen  | Millions of yen | Millions of yen                         | Yen                  |
| Previous Forecast (A)  | 360,000         | 27,000           | 22,000          | 11,500                                  | 129 45               |
| Revised Forecast (B)   | 365,000         | 29,000           | 24,000          | 13,000                                  | 146 32               |
| Change (B-A)   | 5,000           | 2,000            | 2,000           | 1,500                                   |                      |
| Percent Change (%)   | 1.4             | 7.4              | 9.1             | 13.0                                    |                      |
| (Reference)<br>Actual results for the fiscal year ended March 31, 2021 (FY 3/2021) | 337,406         | 26,657           | 20,706          | 4,202                                   | 47 30                |

### 2. Reasons for revision

In the three months ended June 30, 2021, sales of polarizer protective films for LCDs “COSMOSHINE SRF” and mold releasing film for MLCC “COSMOPEEL” achieved growth due to the full-fledged operation of each of their new lines, and sales of raw materials and reagents for PCR testing grew in response to the societal demand for PCR testing.

Although there are uncertainties with regard to the future, such as the resurgence of the spread of the novel coronavirus disease (COVID-19) and the impact of rising raw material prices, the Company has revised the previously announced forecasts for the fiscal year upwards, based on recent sales of industrial films, reagents for PCR testing, etc.

(Note) The above business forecasts have been prepared based on the information available as of the date of this announcement, and actual results may differ from these forecasts due to various factors.